Clinical trials: Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Type 2 Diabetes (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease
Cardiovascular Risk in T2DM With MAFLD: A Cohort Study
This study aims to address the following key scientific question by establishing a large-scale, high-standard clinical cohort: the independent contribution of MASLD and its progression to liver fibrosis on cardiovascular outcomes…
- Trial name
- NCT07706010
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
Metabolic Dysfunction Associated Fatty Liver Disease
Effect of High Protein Diet on Hepatic Steatosis in Patients With MAFLD
MAFLD is a growing problem in India. Its pathophysiology is complex, but focused on abnormal substrate handling due to mitochondrial dysfunction reflecting as metabolic inflexibility. Nutrition is the cornerstone of management.
- Trial name
- NCT06749704
- Testing
- High protein diet, Normal Protein diet
- Where
- India
- Volunteers
- 140 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Post-cholecystectomy Metabolic Changes -Hepatic Steatosis
Fatty Liver in Long Standing Cholecystectomy
This observational study aims to evaluate the association between long-term cholecystectomy and the development of metabolic dysfunction-associated fatty liver disease (MAFLD) in adult patients.
- Trial name
- MAFLD-Chole St (NCT07284004)
- Volunteers
- 100 people
- Sponsor
- Yasmeen Ahmed Farrag Ahmed
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Type 2 Diabetes Mellitus (T2DM)
Adiponectin in Patients With Metabolic Disorders
Background. Metabolic dysfunction-associated fatty liver disease (MAFLD/MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with insulin resistance.
- Trial name
- NCT07539584
- Testing
- SGLT2 inhibitor, GLP-1 RA
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- Moscow Regional Research and Clinical Institute (MONIKI)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic Syndrome
ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study
The ENDOCARE-SCREEN study is a single-center, observational, cross-sectional screening study designed to assess the prevalence, phenotypes, and determinants of metabolic dysfunction-associated steatotic liver disease…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic Syndrome, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- ENDOCARE-SCREE (NCT07336563)
- Where
- Poland
- Volunteers
- 10,000 people
- Sponsor
- Jarosław Drobnik
MAFLD
Liver Stiffness Changes by iLivTouch to Predict Liver-Related Events in MAFLD
This is an observational study (multicenter retrospective real-world cohort study). The purpose of this study is to assess the predictive performance of liver stiffness measurement (LSM, including baseline LSM1, current LSMC and…
- Trial name
- MAFLD (NCT07777198)
- Volunteers
- 2,303 people
- Sponsor
- Beijing Friendship Hospital
MAFLD, Cholecystitis
Metabolic Dysfunction-Associated Fatty Liver Disease Impairs Intraoperative Indocyanine Green Fluorescence Cholangiography Quality: Development and Validation of a Predictive Model
Near-infrared fluorescence cholangiography has been shown to improve the clinical outcomes of laparoscopic cholecystectomy (LC).
- Conditions
- MAFLD, Cholecystitis, Gallbladder Polyps, Cholelithiasis
- Trial name
- NCT07297225
- Testing
- Retrospective observational study without intervention measures
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhujiang Hospital
Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-associated Fatty Liver Disease
- Trial name
- NCT07632677
- Testing
- iLivTouch (Vibration-controlled transient elastography)
- Where
- 22 sites in China
- Volunteers
- 10,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Steatohepatitis, Nonalcoholic
Screening for Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) at Al-Rajhy Hospital Nutrition Clinic. Assiut, Egypt
Primary outcome Screen for MAFLD among patients attending to the Nutrition clinic in Al Rajhi hospital. Secondary outcome Determining the degrees of fibrosis and steatosis in patients with MAFLD Determining the rate of obesity…
- Trial name
- NCT04861012
- Testing
- Ultrasound
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Assiut University
NAFLD
Impact of NAFLD vs MAFLD Stigma on Quality of Life in Egyptian Patients
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of liver disease worldwide. The global burden of NAFLD is about 30% of the population, With a higher prevalence in Egypt about 47.5 %.
- Trial name
- NCT06503068
- Testing
- Questionnaire
- Where
- Egypt
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tanta University
Metabolic Dysfunction-associated Fatty Liver Disease
Efficacy and Safety of Calculus Bovis Sativus in Adults With MAFLD
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become the most common chronic liver disease worldwide. Timely therapeutic intervention for MAFLD is crucial for improving patient prognosis and preventing its…
- Trial name
- NCT07085962
- Testing
- Calculus bovis sativus
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Huazhong University of Science and Technology
Metabolic Dysfunction-Associated Fatty Liver Disease, Obesity, Adolescent
Effect of L-citrulline and HIIT on Arterial Stiffness, Body Composition, and Lipid Profile in Adolescents with Steatosis Associated with Metabolic Dysfunction (MASLD)
Obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) accelerate the appearance of arterial stiffness due to inflammatory and oxidative stress mechanisms producing increased vascular tone and increasing the…
- Conditions
- Metabolic Dysfunction-Associated Fatty Liver Disease, Obesity, Adolescent, Arterial Stiffness
- Trial name
- NCT05778266
- Testing
- L-citrulline, Carboxymethyl cellulose, High Intensity Intervals Training
- Where
- Mexico
- Volunteers
- 43 people
- Sponsor
- Universidad de Guanajuato
Metabolic Dysfunction-Associated Fatty Liver Disease
CPET-based HIIT for MAFLD
High-intensity interval training (HIIT), as an individualized exercise training mode based on cardiopulmonary exercise testing (CPET), is characterized by high-intensity training sessions interspersed with short rest periods.
- Trial name
- CEPHIT (NCT07177963)
- Testing
- HIIT, No specific exercise intervention.
- Where
- 5 sites in China
- Volunteers
- 54 people
- Sponsor
- Tang Yida
Chronic Kidney Diseases, MAFLD
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.
This project aims to investigate how Chronic Kidney Disease (CKD) develops and progresses in patients who also have Non-Alcoholic Fatty Liver Disease (NAFLD) and to evaluate whether oral semaglutide (a GLP-1 receptor agonist) can…
- Trial name
- NCT07391267
- Testing
- Semaglutide Oral Tablet, Standard medical treatment
- Where
- India
- Volunteers
- 90 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Fatty Liver, NAFLD
Effect of CoQ10 on the Outcome of MAFLD Patients
So far there has been no universal treatment for MAFLD since it has a complex etiology that involves ethnic, genetic, metabolic and environmental factors.
- Trial name
- NCT05984745
- Testing
- Coenzyme Q10 Forte® capsules
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
MAFLD
Semaglutide Effectiveness in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease in the Real World Practice
This real-world clinical trial evaluates the effectiveness of semaglutide (target dose is 2.4 mg/week) over 154 weeks (3 years) prescribed to the patients with metabolic dysfunction-associated fatty liver disease (MAFLD) and…
- Trial name
- NCT06983171
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- Center of target therapy
Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis
Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic…
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis, Liver Fibrosis
- Trial name
- NCT05974904
- Testing
- high-sensitivity C-reactive protein to albumin ratio
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- Chongqing Medical University
Metabolic Dysfunction-associated Fatty Liver Disease, Metabolic Disease
NMR-based Metabolic Profiling Identifies High Risk of MAFLD Patients With Advanced Fibrosis
This study aim to find out metabolic molecules in blood and urine which could identify high risk of advanced fibrosis in MAFLD patients via NMR-based metabolic profiling.
- Trial name
- NCT05734599
- Testing
- NMR-based metabolic profiling
- Where
- China
- Volunteers
- 1,194 people, healthy volunteers welcome
- Sponsor
- Huazhong University of Science and Technology
Fatty Liver Disease
Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China
- Trial name
- MAFLD (NCT05421572)
- Testing
- Fibrotouch
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH)
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches.
- Conditions
- Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH), Obesity
- Trial name
- METAfoie (NCT06764056)
- Testing
- semaglutide, Diet
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval